Berenbaum, Francis http://orcid.org/0000-0001-8252-7815
Blanco, Francisco J http://orcid.org/0000-0001-9821-7635
Guermazi, Ali
Miki, Kenji
Yamabe, Takaharu
Viktrup, Lars
Junor, Rod
Carey, William
Brown, Mark T
West, Christine R
Verburg, Kenneth M
Clinical trials referenced in this document:
Documents that mention this clinical trial
Response to: ‘Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues’ by Riddle and Perera
https://doi.org/10.1136/annrheumdis-2020-217629
Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period (Results)
https://doi.org/10.1136/annrheumdis-2019-216296
FRI0392 ADVERSE EVENTS IN PATIENTS WITH OSTEOARTHRITIS TREATED WITH SUBCUTANEOUS TANEZUMAB: A POOLED ANALYSIS OF THE OVERALL POPULATION AND SELECTED SUBGROUPS FROM 3 RANDOMISED PLACEBO-CONTROLLED TRIALS
https://doi.org/10.1136/annrheumdis-2020-eular.3701
A Two-Step, Trajectory-Focused, Analytics Approach to Attempt Prediction of Analgesic Response in Patients with Moderate-to-Severe Osteoarthritis
https://doi.org/10.1007/s12325-022-02336-6
AB0859 IMPROVEMENTS IN PHYSICAL FUNCTION IN PATIENTS WITH OSTEOARTHRITIS RECEIVING SUBCUTANEOUS TANEZUMAB IN 3 RANDOMIZED CONTROLLED TRIALS
https://doi.org/10.1136/annrheumdis-2020-eular.953
Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis
https://doi.org/10.1007/s40261-023-01286-3
Documents that mention this clinical trial
Response to: ‘Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues’ by Riddle and Perera
https://doi.org/10.1136/annrheumdis-2020-217629
Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period
https://doi.org/10.1136/annrheumdis-2019-216296
A Two-Step, Trajectory-Focused, Analytics Approach to Attempt Prediction of Analgesic Response in Patients with Moderate-to-Severe Osteoarthritis
https://doi.org/10.1007/s12325-022-02336-6
POS1088 EFFICACY OF SUBCUTANEOUS TANEZUMAB FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE OR HIP: A POST-HOC SUBGROUP ANALYSIS OF PATIENTS FROM A RANDOMIZED, NSAID-CONTROLLED STUDY WITH A HISTORY OF DEPRESSION, ANXIETY, OR INSOMNIA
https://doi.org/10.1136/annrheumdis-2021-eular.166
AB0859 IMPROVEMENTS IN PHYSICAL FUNCTION IN PATIENTS WITH OSTEOARTHRITIS RECEIVING SUBCUTANEOUS TANEZUMAB IN 3 RANDOMIZED CONTROLLED TRIALS
https://doi.org/10.1136/annrheumdis-2020-eular.953
Documents that mention this clinical trial
Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period
https://doi.org/10.1136/annrheumdis-2019-216296
Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis
https://doi.org/10.1007/s40261-023-01286-3
Documents that mention this clinical trial
Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period
https://doi.org/10.1136/annrheumdis-2019-216296
Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis
https://doi.org/10.1007/s40261-023-01286-3
Documents that mention this clinical trial
Response to: ‘Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues’ by Riddle and Perera
https://doi.org/10.1136/annrheumdis-2020-217629
Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period (Results)
https://doi.org/10.1136/annrheumdis-2019-216296
FRI0392 ADVERSE EVENTS IN PATIENTS WITH OSTEOARTHRITIS TREATED WITH SUBCUTANEOUS TANEZUMAB: A POOLED ANALYSIS OF THE OVERALL POPULATION AND SELECTED SUBGROUPS FROM 3 RANDOMISED PLACEBO-CONTROLLED TRIALS
https://doi.org/10.1136/annrheumdis-2020-eular.3701
A Two-Step, Trajectory-Focused, Analytics Approach to Attempt Prediction of Analgesic Response in Patients with Moderate-to-Severe Osteoarthritis
https://doi.org/10.1007/s12325-022-02336-6
AB0859 IMPROVEMENTS IN PHYSICAL FUNCTION IN PATIENTS WITH OSTEOARTHRITIS RECEIVING SUBCUTANEOUS TANEZUMAB IN 3 RANDOMIZED CONTROLLED TRIALS
https://doi.org/10.1136/annrheumdis-2020-eular.953
Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis
https://doi.org/10.1007/s40261-023-01286-3
Documents that mention this clinical trial
Response to: ‘Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues’ by Riddle and Perera
https://doi.org/10.1136/annrheumdis-2020-217629
Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period
https://doi.org/10.1136/annrheumdis-2019-216296
A Two-Step, Trajectory-Focused, Analytics Approach to Attempt Prediction of Analgesic Response in Patients with Moderate-to-Severe Osteoarthritis
https://doi.org/10.1007/s12325-022-02336-6
POS1088 EFFICACY OF SUBCUTANEOUS TANEZUMAB FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE OR HIP: A POST-HOC SUBGROUP ANALYSIS OF PATIENTS FROM A RANDOMIZED, NSAID-CONTROLLED STUDY WITH A HISTORY OF DEPRESSION, ANXIETY, OR INSOMNIA
https://doi.org/10.1136/annrheumdis-2021-eular.166
AB0859 IMPROVEMENTS IN PHYSICAL FUNCTION IN PATIENTS WITH OSTEOARTHRITIS RECEIVING SUBCUTANEOUS TANEZUMAB IN 3 RANDOMIZED CONTROLLED TRIALS
https://doi.org/10.1136/annrheumdis-2020-eular.953
Funding for this research was provided by:
Pfizer Inc.
Eli Lilly and Company